RxDoctor Payments Data

Michelle Dade

Psychiatric/Mental Health · Atlanta, GANPI 1811460967

Payments from drug & device makers

$1,113in general payments, 2019–2025

Across 48 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$700
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$102
  • Corium, LLC$70
  • Otsuka America Pharmaceutical, Inc.$56
  • Axsome Therapeutics, Inc.$30
  • Teva Pharmaceuticals USA, Inc.$29
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$1,113100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,113 in reported general payments places this provider in the 70th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$19,229
Medicare patients
18
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl25$47,708
RexultiBrexpiprazole31$41,537
Aripiprazole39$5,521
TrintellixVortioxetine Hydrobromide11$4,815
Lurasidone Hcl18$1,138
Quetiapine Fumarate73$702
Bupropion XlBupropion Hcl42$382
Gabapentin23$365
Venlafaxine Hcl ErVenlafaxine Hcl40$305
Prazosin Hcl34$304
Fluoxetine Hcl68$300
Divalproex Sodium ErDivalproex Sodium12$289
Trazodone Hcl72$286
Propranolol Hcl45$271
Escitalopram Oxalate61$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$700$47,70825 claims
Otsuka America Pharmaceutical, Inc.Rexulti$56$41,53731 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$4,81511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →